IL207220B - Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans - Google Patents

Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans

Info

Publication number
IL207220B
IL207220B IL207220A IL20722010A IL207220B IL 207220 B IL207220 B IL 207220B IL 207220 A IL207220 A IL 207220A IL 20722010 A IL20722010 A IL 20722010A IL 207220 B IL207220 B IL 207220B
Authority
IL
Israel
Prior art keywords
medicament
age
prevention
preparation
treatment
Prior art date
Application number
IL207220A
Other languages
English (en)
Hebrew (he)
Other versions
IL207220A0 (en
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of IL207220A0 publication Critical patent/IL207220A0/en
Publication of IL207220B publication Critical patent/IL207220B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL207220A 2008-02-11 2010-07-26 Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans IL207220B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2762508P 2008-02-11 2008-02-11
PCT/US2009/000824 WO2009102418A1 (en) 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction

Publications (2)

Publication Number Publication Date
IL207220A0 IL207220A0 (en) 2010-12-30
IL207220B true IL207220B (en) 2018-04-30

Family

ID=40521846

Family Applications (2)

Application Number Title Priority Date Filing Date
IL207220A IL207220B (en) 2008-02-11 2010-07-26 Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans
IL258356A IL258356A (en) 2008-02-11 2018-03-26 Use of synthetic retinal histology for the preparation of a medicament for the treatment or prevention of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL258356A IL258356A (en) 2008-02-11 2018-03-26 Use of synthetic retinal histology for the preparation of a medicament for the treatment or prevention of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans

Country Status (14)

Country Link
US (7) US8324270B2 (ko)
EP (1) EP2252276B1 (ko)
JP (3) JP6022746B2 (ko)
KR (2) KR101810381B1 (ko)
CN (1) CN101969938A (ko)
AU (1) AU2009213138B2 (ko)
BR (1) BRPI0908154A2 (ko)
CA (2) CA2714530C (ko)
IL (2) IL207220B (ko)
MX (1) MX337656B (ko)
NZ (3) NZ617701A (ko)
RU (1) RU2565448C2 (ko)
WO (1) WO2009102418A1 (ko)
ZA (1) ZA201005434B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327400A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
BRPI0511396B1 (pt) 2004-06-18 2021-07-27 University Of Washington Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético
EP1888548B1 (en) 2005-05-26 2012-08-22 Neuron Systems, Inc Quinoline derivative for the treatment of retinal diseases
WO2009102418A1 (en) * 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
KR101710505B1 (ko) 2009-09-15 2017-02-27 노벨리언 테라퓨틱스 인코포레이티드 리피드 비히클에 9-시스-레티닐 에스테르를 포함하는 약제 처방
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
RU2622763C2 (ru) 2010-04-19 2017-06-19 Новелион Терапьютикс Инк. Лечебная схема и способы лечения или уменьшения нарушений зрения, связанных с дефицитом эндогенных ретиноидов
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
BR112014021602A2 (pt) * 2012-03-01 2021-06-08 Quadra Logic Tech Inc uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide
US9687481B2 (en) * 2013-01-23 2017-06-27 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
MX2018013472A (es) 2016-05-09 2019-02-28 Aldeyra Therapeutics Inc Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
EP3596040B1 (en) 2017-03-16 2023-10-11 Aldeyra Therapeutics, Inc. Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
JP7354508B2 (ja) 2017-10-25 2023-10-03 株式会社ヒラノテクシード ロールの回転装置
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
WO2021062022A1 (en) * 2019-09-25 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
JP2023529932A (ja) * 2020-06-09 2023-07-12 エルミネックス バイオサイエンシズ（スーチョウ）リミティド レチノイド化合物の毎日の低用量投与による視覚障害の治療方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196076A (en) 1961-12-20 1965-07-20 Schering Corp Anti-depressant 10-(3-dimethylaminopropyl)-3-azaphenothiazine
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) * 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
WO2000068354A1 (en) 1999-05-07 2000-11-16 Chemlink Laboratories Llc Window cleaner tablet
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
CN1455780A (zh) 2001-01-11 2003-11-12 株式会社开备传 新视黄醇衍生物、其制备方法和用途
WO2002058586A2 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
JP2005524626A (ja) 2002-01-18 2005-08-18 タットン テクノロジーズ エルエルシー． 眼疾患を治療するための方法
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP2006512279A (ja) 2002-03-29 2006-04-13 マキシム ファーマシューティカルス，インコーポレイテッド 眼内損傷を治療および予防するためのｒｏｍ生成および放出阻害剤の使用
EP2327400A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
KR20060135819A (ko) * 2004-02-17 2006-12-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 황반변성을 포함하는 안과질환의 관리
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
EP1727529B1 (en) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
BRPI0511396B1 (pt) * 2004-06-18 2021-07-27 University Of Washington Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético
EP1768657B1 (en) 2004-06-23 2008-08-13 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivates
EP1778207A2 (en) * 2004-08-18 2007-05-02 Sytera Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
PL2187880T3 (pl) 2007-09-12 2014-05-30 Univ Columbia Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
WO2009102418A1 (en) * 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction

Also Published As

Publication number Publication date
MX337656B (es) 2016-03-14
US9408821B2 (en) 2016-08-09
JP5934304B2 (ja) 2016-06-15
CA2714530A1 (en) 2009-08-20
KR101810381B1 (ko) 2017-12-19
WO2009102418A1 (en) 2009-08-20
CN101969938A (zh) 2011-02-09
AU2009213138A1 (en) 2009-08-20
AU2009213138B2 (en) 2014-11-06
US20100035986A1 (en) 2010-02-11
JP6272943B2 (ja) 2018-01-31
JP2011511789A (ja) 2011-04-14
US20190133986A1 (en) 2019-05-09
US20130072558A1 (en) 2013-03-21
IL207220A0 (en) 2010-12-30
ZA201005434B (en) 2011-11-30
US20130072561A1 (en) 2013-03-21
US20130072557A1 (en) 2013-03-21
JP6022746B2 (ja) 2016-11-09
NZ587376A (en) 2012-06-29
JP2016190852A (ja) 2016-11-10
US20160331713A1 (en) 2016-11-17
NZ600498A (en) 2014-01-31
US20180098955A1 (en) 2018-04-12
CA3018374A1 (en) 2009-08-20
EP2252276B1 (en) 2019-03-27
KR20100126358A (ko) 2010-12-01
JP2014221828A (ja) 2014-11-27
NZ617701A (en) 2015-06-26
CA2714530C (en) 2018-09-25
MX2010008847A (es) 2010-11-30
US9855239B2 (en) 2018-01-02
US8324270B2 (en) 2012-12-04
KR20160092032A (ko) 2016-08-03
US9233091B2 (en) 2016-01-12
EP2252276A1 (en) 2010-11-24
RU2565448C2 (ru) 2015-10-20
RU2010137842A (ru) 2012-03-20
BRPI0908154A2 (pt) 2015-08-11
IL258356A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
IL258356A (en) Use of synthetic retinal histology for the preparation of a medicament for the treatment or prevention of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans
HK1225642A1 (zh) 用於治療假性延髓反應、神經性疾病、頑固性及慢性疼痛以及腦損傷的嗎啡喃化合物和抗抑鬱劑組合
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
IL221744A (en) Use of a combination of compounds to prepare a drug to treat Parkinson's disease
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
ZA200905962B (en) Combination therapy for treatment of immune disorders
IL217777A (en) A peptide for the preparation of pain medication
EP2326173A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CITRUS GREENING DISEASE
PL3338791T3 (pl) Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
IL221276A (en) Combination with Sigma ligand and opioids or opiates for prevention or treatment of pain that develops as a result of surgery
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
WO2013098416A3 (fr) Composes anti-douleur
IL240394B (en) Use of alemtuzumab to prepare a drug for use as a secondary treatment in multiple sclerosis
SI2379066T1 (sl) Uporaba opioidnih antagonistov za pripravo zdravila za zdravljenje degenerativnih bolezni retine
IL207965A (en) Compounds to treat or prevent pain
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
IL218230B (en) Use of lapatinib or an acceptable pharmaceutical salt or preparation thereof for the preparation of a drug for the treatment of cancer
HUP0800498A2 (en) Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed